Annualized costs of contraceptive products in the United States: a comparison of long-acting and short-acting reversible methods
ESC Congress Library. Trussell J. May 28, 2014; 50574; A-159 Disclosure(s): Full-time professor of economics and public affairs at Princeton University; received a consultancy fee from Bayer Pharma AG for contribution to this work.
Prof. James Trussell
Prof. James Trussell
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Rate & Comment (0)

Objectives: This study aimed to compare average annual costs of available reversible contraceptive methods in a cohort of young women in the United States from a payer’s perspective.


Methods: An economic model was developed to estimate relative costs of “no method” (chance), four short-acting reversible (SARC) methods (oral contraceptive, ring, patch and injection) and four long-acting reversible (LARC) methods (implant, IUD, LNG-IUS 20mcg/24hrs (5-year-IUS), and LNG-IUS 13.5mg (total content), a new 3-year levonorgestrel IUS).  The analysis was conducted over a 5-year time horizon in 1000 women aged 20-29 years. The model consisted of three mutually exclusive health states: initial method, unplanned pregnancy and subsequent method. Failure and discontinuation rates were based on published literature. Costs associated with drug acquisition, medical resource and failure were considered and taken from standard US databases. Key model outputs were the annual average cost per method and the minimum duration LARC methods would need to be used before proving cost-saving compared to SARC methods.


Results: The four least expensive methods were IUD ($314USD per women per year), 5-year-IUS ($317USD), implant ($403USD) and 3-year-IUS ($429USD). Average annual cost of SARC methods ranged between $448USD (injection) and $760USD (patch). The analysis found that an average of 1.77 years of LARC usage would result in cost-savings compared to SARC usage.


 


Conclusions: Annual costs of all LARC are lower than those of any SARC. This analysis finds that even if LARC methods are not used for their full durations of efficacy, they become cost-saving relative to SARC methods within 2 years of use.

    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings